Depression is a common symptom in Parkinson's disease (PD) and it is present in up to 40% of the patients. The cause of depression in PD is thought to be related to disturbance of monoamine neurotransmission. The endogenous cannabinoid system mediates different brain processes that play a role in the control of behaviour and emotions. Cannabinoid function may be altered in neuropsychiatry diseases, directly or through interactions with monoamine, GABA and glutamate systems. For this reason, we have investigated whether there is a genetic risk factor for depression in PD linked to the polymorphisms of CB1 receptor gene. Depression was more frequent in patients with PD than in controls with osteoarthritis. The presence of depression did not correlate with the stage of the disease but it was more frequent in patients with pure akinetic syndrome than in those with tremoric or mixed type PD. The CB1 receptor gene polymorphism (AAT)n is considered to modify the transcription of the gene and, therefore, it may have functional relevance. We analysed the length of the polymorphic triplet (AAT)n of the gene that encodes CB1 (CNR1) receptor in 89 subjects (48 PD patients and 41 controls). In patients with PD, the presence of two long alleles, with more than 16 repeated AAT trinucleotides in the CNR1 gene, was associated with a reduced prevalence of depression (Fisher's exact test: P=0.003). This association did not reach significant differences in the control group, but the number of control individuals with depression was too small to allow for statistical analysis. Since the alleles with long expansions may have functional impact in cannabinoid neurotransmission, our data suggest that the pharmacological manipulation of cannabinoid neurotransmission could open a new therapeutic approach for the treatment of depression in PD and possibly in other conditions.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Annals of General Psychiatry Open Access 17 March 2023
Depression in Patients with Parkinson’s Disease: Current Understanding of its Neurobiology and Implications for Treatment
Drugs & Aging Open Access 16 June 2022
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Tanner CM, Goldman SM . Epidemiology of Parkinson's disease. Neurol Clin 1996; 14: 317–335.
Gibb WRG, Lees AJ . Pathological clues to the cause of Parkinson's disease. In: Marsden CD, Fahn S (eds). Movement Disorders, vol. 3. Butterworth-Heinemann: Oxford, 1994, pp 146–166.
Chia LG, Cheng LJ, Chuo LJ, Cheng FC, Cu JS . Studies of dementia, depression, electrophysiology and cerebrospinal fluid monoamine metabolites in patients with Parkinson's disease. J Neurol Sci 1995; 133: 73–78.
Cummings LF . Depression and Parkinson's disease: a review. Am J Psychiatric 1992; 149: 443–454.
Tandberg E, Larsen JP, Arsland D, Cummings JL . The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol 1996; 53: 175–179.
McDonald WM, Richard IH, DeLong MR . Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 2003; 54: 363–375.
Serrano-Dueñas M . A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson's disease. Rev Neurol 2002; 35: 1010–1014.
Kostic VS, Filipovic SR, Lecic D, Momcilovic D, Sokic D, Sternic N . Effect of age at onset on frequency of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 1265–1267.
Mayeux R, Stern Y, Rosen J, Leventhal J . Depression intellectual impairment and Parkinson's disease. Neurology 1981; 31: 645–650.
Mayeux R . Behavioral manifestations of movement disorders. Neurol Clin 1984; 2: 527–540.
Huber SJ, Paulson GW, Shuttleworth EC . Relationship of motor symptoms, intellectual impairment, and depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998; 51: 855–858.
Liu C-Y, Wang S-J, Fuh J-L, Liu CH, Yang YY, Liu HC . The correlation of depression with functional activity in Parkinson's disease. J Neurol 1997; 244: 493–498.
Gil Saladié D, Delgado González M . y cols. La depresión de la enfermedad de Parkinson y su relación con las manifestaciones cognitivas y motoras. Neurología 1992; 7: 176–179.
Hammond-Tooke G, Pollock M . Depression, dementia, and Parkinson's disease. In: Hoseph AB, Young RR (eds). Movement Disorders in Neurology and Neuropsychiatry, 2 edn. Blackwell Science: Massachusetts, 1999, pp 195–204.
Meltzer HY, Lowy MT . The serotonin hypothesis of depression. In: Meltzer HY (eds). Psychopharmacology: The Third Generation of Progress. Raven Press: New York, 1987, pp 513–526.
Howlett AC, Bidaut-Rusell M, Devane WA, Melvin LS, Johnson MR, Herkenham M . The cannabinoid receptor: biochemical, anatomical and behavioural characterization. Trends Neurosci 1990; 13: 420–423.
Tsout K, Brown S, Sañudo-Peña MC, Mackie K, Walker JM . Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998; 83: 393–411.
Hoehe MR, Caenazzo L, Martinez MM, Hsieh WT, Modi WS, Gershon ES et al. Genetic and physical mapping of the human cannabinoid receptor gene chromosome 6q14–q15. New Biol 1991; 3: 880–885.
Gerard CM, Mollereau C, Vassart G, Parmentier M . Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991; 279: 129–134.
Hermann H, Marsicano G, Lutz B . Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002; 109: 451–460.
Sieradzan KA, Fox SH, Hill M, Disck JP, Crossman AR, Brotchie JM et al. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001; 57: 2108–2111.
Sañudo-Peña MC, Tsoy K, Walker JM . Motor action of cannabinoids in the basal ganglia output nuclei. Life Sci 1999; 65: 713.
Lastres-Becker I, Cebeira M, de Cevallos M, Zeng B-Y, Jenner P, Ramos JA . Fernández–Ruiz increased cannabinoid CB1 receptor binding and activation of GPT-binding proteins in the basal ganglia of patients with Parkinson's disease and MPTP-treated marmosets. Eur J Neurosci 2001; 14: 1827–1832.
Rottanburg D, Robins AH, Ben-Arie O, Teggin A, Elk R . Cannabis associated psychosis with hipomanic features. Lancet 1982; 2: 1364–1366.
Devane AA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC . Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605–613.
Matsuda LA, Bonner TI, Lolait SJ . Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 1993; 327: 535–550.
Banerjee SP, Synder SH, Mechulam R . Cannabinoids: L influence on neurotransmitter uptake in rat brain synaphosomes. J Pharmacol Exp Ther 1975; 194: 74–81.
Musty RE, Kaback L . Relationships between motivation and depression in chronic marijuana users. Life Sci 1995; 56: 2151–2158.
Mato S, Rodriguez-Puertas R, González-Maeso J, Meana J, Sallés J, Pazos A . Receptores centrales para cannabinoides en cerebro humano postmortem: estudio radiométrico en la depresión mayor. 1a Reunión nacional sobre investigación en cannabinoides, Madrid, 2000.
Robbe D, Kopf M, Remaury A, Bockaert J, Manzoni OJ . Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci USA 2002; 99: 8384–8388.
Wainwright NWJ, Surtees PG . Childhood adversity, gender and depression over the life-course. J Affect Disorders 2002; 72: 33–44.
Martin M, Ledent C, Parmentir M, Maldonado R, Valverde O . Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 2002; 159: 379–387.
Dawson E . Identification of a polymorphic triplet repeat marker for the brain cannabinoid receptor gene: use in linkage and association studies. Psychiat Genet 1995; 5: S50.
Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045–2047.
Mizuno Y, Hattori N, Mori H, Suzuki T, Tanaka K . Parkin and Parkinson's disease. Curr Opin Neurol 2001; 14: 477–482.
Vaughan JR, Davis MB, Wood NW . Genetics of Parkinsonism: a review. Ann Hum Genet 2001; 65: 111–126.
Tan EK, Khajavi M, Thornby JL, Nagamitsu S, Jankovic J, Ashizawa T . Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 2000; 55: 533–538.
Schroth GP, Chou PJ, Ho PS . Mapping Z-DNA in the human genome. Computer-aided mapping reveals a nonrandom distribution of potential Z-DNA-forming sequences in human genes. J Biol Chem 1992; 267: 11846–11855.
Comings DE . Polygenic inheritance and minisatellites. Psychiat Genet 1996; 6: 157–158.
Tsai SJ, Wang YC, Hong CJ . Association study between cannabonoid receptor gene (CNR1) and pathogenesis and psychotic symptoms of mood disorders. Am J Med Genet 2001; 105: 219–221.
Comings DE, Muhleman D, Gade R, Jonson P, Verde R, Saucier G et al. Cannabinoid receptor gene (CNR1): association with IV drug abuse. Mol Psychiatry 1997; 2: 161–168.
Lutz G, Schmidt T, Samochowiec J, Finckh U, Fiser-Piosik E, Horodinicki J et al. Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depen 2002; 65: 221–224.
Ujike H, Takaki M, Nakata K, Tanaka Y, Takeda T, Kodama M et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 2002; 7: 515–518.
Heller D, Schneider U, Seifert J, Cimander KF, Stuhrmann M . The cannabinoid receptor gene (CNR1) is not affected in German i.v. drugs users. Addict Biol 2001; 6: 183–187.
Li T, Liu X, Zhu ZH, Zhao J, Hu X, Ball DM et al. No association between (AAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population. Mol Psychiatry 2000; 5: 128–130.
Hungund BL, Vinod KY, Kassir SA, Basavarajappa BS, Yalamanchili R, Cooper TB et al. Upregulation of CB1 receptors and agonist-stimulated [35S] GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry 2004; 9: 184–190.
Melamed E . Neurobehavioral abnormalities in Parkinson's disease. In: Watt RL, Koller WC (eds). Movement Disorders. Neurologic Principles and Practice. McGraw-Hill: New York, 1997, pp 257–261.
Errea-Abad JM, Ara-Callizo JR, Aibar-Remón C . Drug-induced Parkinsonism. Clinical aspects compared with Parkinson disease. Rev Neurol 1998; 27: 35–39.
Mayberg HS, Solomon DH . Depression in Parkinson's disease: a biochemical and organic viewpoint. Adv Neurol 1995; 65: 49–60.
Hantz P, Caradoc-Davis G, Caradoc-Davis T, Weatherall M, Dixon G . Depression in Parkinson's disease. Am J Psychiatry 1994; 151: 1010–1014.
Santamaría J, Tolosa E, Valles A . A Parkinson's disease with depression: a possible subgroup of idiopathic Parkinsonism. Neurology 1986; 36: 1130–1133.
Starkstein SE, Petracca G, Chemerinski E, Teson A, Sabe L, Merello M et al. Depression in classic versus akinetic-rigid Parkinson's disease. Mov Disord 1998; 13: 29–33.
Mayeux R, Stern Y, Rosen J, Leventhal J . Depression, intellectual impairment and Parkinson's disease. Neurology 1991; 31: 645–650.
Ponce G, Hoenicka J, Rubio G, Ampuero I, Jiménez-Arriero MA, Rodríguez-Jimenez R et al. Association between the cannabinoid receptor gene (CNR1) and childhood attention-deficit/hyperactivity disorder in Spanish male alcoholic, patients. Mol Psychiatry 2003; 8: 466–467.
Macritchie KA, Young AH . Emerging targets for the treatment of depressive disorder. Expert Opin Ther targets 2001; 5: 601–612.
Gelb DJ, Oliver E, Gliman S . Diagnostic criteria for Parkinson Disease. Arch Neurol 1999; 56: 33–39.
Hoehn MM, Yahr MD . Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427–442.
Fahn S, Elton RL . Members of the UPDRS Development Committee: Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds). Recent Developments in Parkinson's Disease, vol. 2. Macmillan Healthcare information: Florham Park, NJ, 1987, pp 153–163, 293–304.
Hamilton M . A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62.
This work has been possible owing to a research grant from Fondo de Investigaciones Sanitarias year 2000, number 00/0785, to D Blas Morales and support from Centro Investigaciones sobre Enfermedades Neurologicas and to Dr Justo García de Yébenes, years 2003 and 2004. Israel Ampuero was a research fellow of Fondo de Investigaciones.
About this article
Cite this article
Barrero, F., Ampuero, I., Morales, B. et al. Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1). Pharmacogenomics J 5, 135–141 (2005). https://doi.org/10.1038/sj.tpj.6500301
- Parkinson's disease
- cannabinoid system
This article is cited by
Annals of General Psychiatry (2023)
Therapeutic Molecular Insights into the Active Engagement of Cannabinoids in the Therapy of Parkinson’s Disease: A Novel and Futuristic Approach
Neurotoxicity Research (2023)
Depression in Patients with Parkinson’s Disease: Current Understanding of its Neurobiology and Implications for Treatment
Drugs & Aging (2022)
Journal of Molecular Neuroscience (2021)
Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson’s Disease
Molecular Neurobiology (2019)